Targeting tumor O‐glycosylation modulates cancer–immune‐cell crosstalk and enhances anti‐ PD ‐1 immunotherapy in head and neck cancer
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13489 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Mei-Chun Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Interleukin-6, Head and Neck Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, National Health Research Institutes, Excellent Translational Medicine Research Projects of National Taiwan University College of Medicine and National Taiwan University.
Abstract (Originalsprache)
Cells in the tumor microenvironment (TME) communicate via membrane‐bound and secreted proteins, which are mostly glycosylated. Altered glycomes of malignant tumors influence behaviors of stromal cells. In this study, we showed that the loss of core‐1 β1,3‐galactosyltransferase (C1GALT1)‐mediated O‐glycosylation suppressed tumor growth in syngeneic head and neck cancer mouse models. O‐glycan truncation in tumor cells promoted the M1 polarization of macrophages, enhanced T‐cell‐mediated cytotoxicity, and reduced interleukin‐6 (IL‐6) levels in the secretome. Proteasomal degradation of IL‐6 was controlled by the O‐glycan at threonine 166. Both IL‐6/IL‐6R blockade and O‐glycan truncation in tumor cells induced similar pro‐inflammatory phenotypes in macrophages and cytotoxic T lymphocytes (CTLs). The combination of the O‐glycosylation inhibitor itraconazole and anti‐programmed cell death protein 1 (anti‐PD‐1) antibody effectively suppressed tumor growth in vivo . Collectively, our findings demonstrate that O‐glycosylation in tumor cells governs their crosstalk with macrophages and CTLs. Thus, targeting O‐glycosylation successfully reshapes the TME and consequently enhances the efficacy of anti‐PD‐1 therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.
- Instrumentation Center, National Taiwan University, Taipei, Taiwan.
- Graduate Institute of Anatomy and Cell Biology, College of Medicine, National Taiwan University, Taipei, Taiwan.
ORCID-Profile: Min-Chuan Huang, Pei-Jen Lou
Förderung
- Ministry of Science and Technology, Taiwan
- National Health Research Institutes
- Excellent Translational Medicine Research Projects of National Taiwan University College of Medicine and National Taiwan University
Zitieren
APA
Lin, M. C., Chuang, Y. T., Wu, H. Y., Hsu, C. L., Lin, N. Y., Huang, M. C., & Lou, P. J. (2024). Targeting tumor O‐glycosylation modulates cancer–immune‐cell crosstalk and enhances anti‐ PD ‐1 immunotherapy in head and neck cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.13489
Vancouver
Lin MC, Chuang YT, Wu HY, Hsu CL, Lin NY, Huang MC, et al. Targeting tumor O‐glycosylation modulates cancer–immune‐cell crosstalk and enhances anti‐ PD ‐1 immunotherapy in head and neck cancer. Molecular Oncology. 2024. doi:10.1002/1878-0261.13489
BibTeX
@article{Lin2024,
author = {Lin, Mei-Chun and Chuang, Ya-Ting and Wu, Hsin-Yi and Hsu, Chia-Lang and Lin, Neng-Yu and Huang, Min-Chuan and Lou, Pei-Jen},
title = {Targeting tumor O‐glycosylation modulates cancer–immune‐cell crosstalk and enhances anti‐ PD ‐1 immunotherapy in head and neck cancer},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13489}
}
EUVIMED